三阴性乳腺癌的新辅助化疗

三阴性乳腺癌是一类侵袭性较强且具有明显异质性的乳腺癌亚型,患者的总体预后较差。多项研究显示新辅助化疗后病理完全缓解的三阴性乳腺癌患者预后较好。目前已有多种化疗药物及靶向药物用于三阴性乳腺癌新辅助化疗的临床研究,部分药物显示出较高的病理学完全缓解率和良好的应用前景。

Neoadjuvant chemotherapy for triple-negative breast cancer

Triple-negative breast cancer is a clinically relevant term referring to a specific subtype of breast cancers with aggressive characteristics, strong heterogeneity and shorter survival. Plenty of studies suggest patients who are pathological complete response after neoadjuvant chemotherapy could enjoy brighter prognosis. Currently, many agents including targeting drugs have been explored in clinical trials, several of them have high pCR rates and show promising. In this article, the endpoint and indication of TNBC neoadjuvant chemotherapy, as well as clinical evidence of cytotoxic agents and targeting treatment are summarized.